Skip to main content

Table 1 Demographic and clinical characteristics of patients hospitalized at Intensive Care Unit

From: Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients

Characteristic – n (%) Total (N = 157) Solid tumor (n = 104) Hematological malignancies (n = 53) P-value
Gender – Masculine 80 (51) 43 (41.3) 37 (69.8) <0.001
Age (years)a 48 ± 15 50.5 ± 15.5 43.9 ± 15.7 0.009
Comorbiditiesb     0.257
Arterial hypertension
Diabetes mellitus
Smoking
Obesity
HIV
Other
31 (19.7)
29 (18.5)
19 (12.1)
19 (12.1)
2 (1.3)
13 (8.3)
23 (22.1)
23 (22.1)
13 (12.5)
15 (15.4)
1 (1)
8 (7.7)
8 (15.1)
6 (11.3)
6 (11.3)
4 (7.5)
3 (5.7)
5 (9.4)
Type of tumorc    
NHL
HL
Acute leukemia
Myeloma multiple
Myelodysplastic
Germ cell tumors
Gastrointestinal
Cervical
Breast
Skin and soft tissue
Ovarian
Head and neck
Other tumors
22 (14)
2 (1.3)
22 (14)
4 (2.5)
4 (2.5)
12 (7.6)
23 (14.6)
10 (6.4)
10 (6.4)
10 (6.4)
8 (5.1)
7 (4.5)
20 (12.7)
-
-
-
-
12 (11.5)
23 (22.1)
10 (9.6)
10 (9.6)
10 (9.6)
8 (7.7)
7 (6.7)
20 (19.2)
22 (41.5)d
2 (3.8)
22 (41.5)
4 (7.5)
4 (7.5)
-
-
-
-
-
-
Stagee     
I-II
III-IV
38 (36.2)
67 (63.8)
33 (86.8)
5 (13.2)
50 (74.6)
17 (25.4)
0.211
Oncologic status     0.03
Recent diagnosis
Progression
Relapse
Complete remission
96 (61.1)
30 (19.1)
19 (12.1)
12 (7.6)
57 (54.8)
21 (20.2)
14 (13.5)
12 (11.5)
39 (73.6)
9 (17)
5 (9.4)
0
Chemotherapy in the last 30 daysf 48 (30.6) 19 (18.3) 29 (54.7) <0.001
Radiotherapy in the last 6 months 11 (7) 3 (2.9) 8 (15.1) 0.007
Neutropeniag 9 (5.7) 4 (3.8) 5 (9.4) 0.02
Pancytopenia 20 (12.7) 1 (1) 19 (35.8) <0.001
Hospitalization in the last 90 days 45 (28.7) 21 (20.2) 24 (45.3) 0.001
ICU admission     <0.001
Respiratory failure
Septic shock
Hypovolemic shock
Postsurgical
Post-CPR
Other causesh
54 (34.4)
34 (21.7)
29 (18.5)
13 (8.3)
7 (4.4)
20 (12.7)
25 (24)
20 (19.2)
28 (26.9)
13 (12.6)
6 (5.8)
12 (11.5)
29 (54.7)
14 (26.4)
1 (1.9)
0
1 (1.9)
8 (15.1)
Days from hospitalization to ICU admissioni 2 (1,8) 0 (1,7) 4 (1,13) 0.02
APACHE-II scoreaj 18.9 ± 6.4 18.4 ± 6.7 19.9 ± 5.6 0.134
SOFA scoreak 8.6 ± 3.6 8.4 ± 3.9 9.2 ± 3.1 0.197
  1. aMean ± standard deviation
  2. b HIV human immunodeficiency virus; other comorbidities: 4 patients with thyroid dysfunction. 1 with chronic kidney failure, 2 with chronic liver failure, 1 with Down syndrome, 1 with ischemic heart disease, 3 with neurologic disease and1 with rheumatologic disease
  3. c NHL non-Hodgkin lymphoma; HL = Hodgkin lymphoma; other tumors: lung, bladder, kidney, peripheral nerve, brain
  4. dOne patient who received hematopoietic stem cell transplantation
  5. eStage was documented in 105 patients: 38 solid and 67 hematologic, percentage was calculated with these numbers. The rest of the patients were not stratified because had a neoplasia unclassifiable
  6. fOne patient received sorafenib for kidney cancer and one receive bortezomib for multiple myeloma. Three patients received radiotherapy with concomitant chemotherapy
  7. gFour patients had anemia plus neutropenia, and five had neutropenia plus thrombocytopenia
  8. hKidney failure, cerebrovascular accident, water-electrolyte imbalance, metabolic acidosis and neurologic impairment
  9. iMedian (interquartile range)
  10. jAcute Physiology and Chronic Health Evaluation
  11. kSequential Organ Failure Assessment